Back to Trial Categories

Cancer Trials

Disease: Colorectal
A Phase I / Randomized Phase II Study of Second Line Therapy with Irinotecan and Cetuximab with or without RAD001 (an mTOR Inhibitor) for Patients with Metastatic Colorectal Cancer - GI05-102
Status: Suspended to Accrual to control accrual to cohort; Originally opened to Accrual 08-02-2007 - 27 of 119 Patients Accrued
More Details